HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Paul Emery Selected Research

Psoriatic Arthritis

6/2022Treat-to-target in psoriatic arthritis-cost-effective in the biosimilar era.
1/2022Dactylitis is an indicator of a more severe phenotype independently associated with greater SJC, CRP, ultrasound synovitis and erosive damage in DMARD-naive early psoriatic arthritis.
1/2021Ultrasound shows swollen joints are the better proxy for synovitis than tender joints in DMARD-naïve early psoriatic arthritis.
1/2020A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.
1/2019Regression of Peripheral Subclinical Enthesopathy in Therapy-Naive Patients Treated With Ustekinumab for Moderate-to-Severe Chronic Plaque Psoriasis: A Fifty-Two-Week, Prospective, Open-Label Feasibility Study.
10/2017The dynamics of response as measured by multiple composite outcome tools in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial.
7/2017The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomes.
8/2016Enriching case selection for imminent RA: the use of anti-CCP antibodies in individuals with new non-specific musculoskeletal symptoms - a cohort study.
12/2015Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial.
2/2014Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Paul Emery Research Topics

Disease

276Rheumatoid Arthritis
02/2024 - 02/2002
45Synovitis
02/2024 - 03/2002
43Arthritis (Polyarthritis)
04/2024 - 08/2002
40Inflammation (Inflammations)
02/2024 - 02/2002
36Necrosis
11/2020 - 01/2004
23Infections
02/2023 - 06/2004
22Pain (Aches)
02/2024 - 03/2007
19Ankylosing Spondylitis
11/2021 - 01/2003
19Rheumatic Diseases (Rheumatism)
01/2019 - 12/2003
18Psoriatic Arthritis
06/2022 - 02/2003
17Systemic Lupus Erythematosus (Libman-Sacks Disease)
01/2023 - 01/2004
16Autoimmune Diseases (Autoimmune Disease)
02/2023 - 01/2004
11Fatigue
09/2019 - 09/2006
8Arthralgia (Joint Pain)
02/2024 - 10/2006
7Edema (Dropsy)
01/2022 - 02/2002
7Osteitis
01/2021 - 11/2011
6Juvenile Arthritis (Juvenile Idiopathic Arthritis)
01/2023 - 05/2009
6Fibrosis (Cirrhosis)
12/2021 - 11/2013
6Neoplasms (Cancer)
03/2020 - 01/2005
6Chronic Disease (Chronic Diseases)
09/2019 - 02/2002
6Psoriasis (Pustulosis Palmaris et Plantaris)
01/2019 - 06/2007
6Systemic Scleroderma (Systemic Sclerosis)
01/2019 - 11/2002
6Disease Progression
01/2018 - 01/2003
5Skin Diseases (Skin Disease)
01/2020 - 05/2008
5Osteoarthritis
07/2013 - 08/2002
4COVID-19
02/2023 - 07/2020
4Body Weight (Weight, Body)
12/2015 - 11/2003
3Melanoma (Melanoma, Malignant)
12/2022 - 08/2016
3Tenosynovitis
11/2021 - 10/2007
3Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
01/2021 - 08/2013
3Neutropenia
11/2019 - 12/2015
3Periodontal Diseases (Periodontal Disease)
01/2019 - 09/2015
3Hypertension (High Blood Pressure)
01/2018 - 03/2007
3Interstitial Lung Diseases (Interstitial Lung Disease)
01/2017 - 11/2002
3Joint Diseases (Joint Disease)
02/2014 - 01/2008

Drug/Important Bio-Agent (IBA)

85Methotrexate (Mexate)FDA LinkGeneric
09/2023 - 02/2002
55Antirheumatic Agents (DMARD)IBA
02/2024 - 11/2003
53Rituximab (Mabthera)FDA Link
12/2023 - 06/2004
35Abatacept (Orencia)FDA Link
02/2024 - 06/2002
34Etanercept (Enbrel)FDA Link
09/2023 - 01/2004
31Biomarkers (Surrogate Marker)IBA
02/2024 - 11/2003
29Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2023 - 07/2002
25AutoantibodiesIBA
01/2023 - 10/2003
25Infliximab (Remicade)FDA Link
01/2020 - 01/2004
24Tumor Necrosis Factor InhibitorsIBA
11/2021 - 01/2003
23Adalimumab (Humira)FDA Link
01/2020 - 01/2003
18Anti-Citrullinated Protein AntibodiesIBA
04/2024 - 09/2010
16golimumabFDA Link
01/2020 - 08/2009
15tocilizumab (atlizumab)FDA Link
11/2020 - 12/2007
14AntibodiesIBA
04/2024 - 12/2015
14CytokinesIBA
03/2021 - 03/2004
14Monoclonal AntibodiesIBA
01/2019 - 11/2004
13Proteins (Proteins, Gene)FDA Link
02/2024 - 02/2003
13Rheumatoid FactorIBA
02/2024 - 11/2003
13baricitinibIBA
01/2021 - 01/2017
13C-Reactive ProteinIBA
01/2019 - 11/2003
12Interleukin-6 (Interleukin 6)IBA
01/2023 - 02/2012
12Biosimilar PharmaceuticalsIBA
06/2022 - 03/2014
12Certolizumab PegolFDA Link
01/2020 - 11/2008
11GlucocorticoidsIBA
11/2023 - 05/2006
11ametantrone (HAQ)IBA
01/2022 - 09/2006
11Leflunomide (Arava)FDA LinkGeneric
01/2020 - 02/2002
10Peptides (Polypeptides)IBA
04/2024 - 10/2012
8cyclic citrullinated peptideIBA
02/2024 - 09/2009
8secukinumabIBA
01/2019 - 11/2013
7Immunoglobulin G (IgG)IBA
02/2023 - 12/2007
7Cyclophosphamide (Cytoxan)FDA LinkGeneric
12/2016 - 03/2002
7Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA
04/2014 - 08/2002
6Adrenal Cortex Hormones (Corticosteroids)IBA
02/2024 - 12/2006
6Janus Kinase InhibitorsIBA
11/2023 - 06/2017
6Interleukin-7 (Interleukin 7)IBA
12/2022 - 01/2005
5Janus KinasesIBA
12/2023 - 06/2017
5InterferonsIBA
01/2023 - 01/2016
5EpitopesIBA
01/2022 - 05/2008
5MethylprednisoloneFDA LinkGeneric
11/2021 - 11/2002
5Sulfasalazine (Azulfidine)FDA LinkGeneric
01/2020 - 06/2004
5amsonic acid (DAS)IBA
03/2019 - 12/2003
5Interleukin-17 (Interleukin 17)IBA
01/2018 - 11/2013
5HLA-B27 Antigen (HLA B27 Antigen)IBA
09/2013 - 02/2002
5GadoliniumIBA
08/2009 - 02/2002
4Prednisolone (Predate)FDA LinkGeneric
02/2023 - 12/2006
4sarilumabIBA
11/2020 - 06/2017
4EnzymesIBA
07/2020 - 06/2004
4Immunoglobulins (Immunoglobulin)IBA
08/2015 - 12/2007
4Interleukin-6 Receptors (Interleukin 6 Receptor)IBA
04/2013 - 12/2007
3AntigensIBA
02/2024 - 11/2003
3VaccinesIBA
02/2023 - 01/2017
3Antineutrophil Cytoplasmic Antibodies (ANCA)IBA
01/2021 - 09/2015
3Interferon Type IIBA
12/2020 - 10/2017
3upadacitinibIBA
01/2020 - 12/2016
3AutoantigensIBA
11/2017 - 07/2013
3HLA-DRB1 Chains (HLA DRB1)IBA
01/2010 - 05/2008

Therapy/Procedure

107Therapeutics
02/2024 - 02/2002
10Biological Therapy
01/2023 - 01/2007
7Aftercare (After-Treatment)
01/2019 - 02/2007
4Drug Therapy (Chemotherapy)
07/2012 - 01/2004
3Retreatment
01/2021 - 12/2011
3Drug Tapering
01/2020 - 01/2018
3Remission Induction
08/2013 - 01/2005
3Injections
01/2011 - 01/2004